In the last trading session, 1.11 million Xeris Biopharma Holdings Inc (NASDAQ:XERS) shares changed hands as the company’s beta touched 1.81. With the company’s per share price at $3.20 changed hands at -$0.08 or -2.44% during last session, the market valuation stood at $477.06M. XERS’s last price was a discount, traded about -20.94% off its 52-week high of $3.87. The share price had its 52-week low at $1.69, which suggests the last value was 47.19% up since then. When we look at Xeris Biopharma Holdings Inc’s average trading volume, we note the 10-day average is 1.58 million shares, with the 3-month average coming to 1.64 million.
Analysts gave the Xeris Biopharma Holdings Inc (XERS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XERS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Xeris Biopharma Holdings Inc’s EPS for the current quarter is expected to be -0.05.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Instantly XERS was in red as seen at the end of in last trading. With action -9.60%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -5.60%, with the 5-day performance at -9.60% in the red. However, in the 30-day time frame, Xeris Biopharma Holdings Inc (NASDAQ:XERS) is -8.83% down. Looking at the short shares, we see there were 10.19 million shares sold at short interest cover period of 6.21 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5.8, meaning bulls need an upside of 44.83% from its current market value. According to analyst projections, XERS’s forecast low is 5 with 6.6 as the target high. To hit the forecast high, the stock’s price needs a -106.25% plunge from its current level, while the stock would need to soar -56.25% for it to hit the projected low.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
Data shows that the Xeris Biopharma Holdings Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 29.03% over the past 6 months, a 8.89% in annual growth rate that is considerably lower than the industry average of 16.30%. Year-over-year growth is forecast to reach 23.85% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 60M. 3 analysts are of the opinion that Xeris Biopharma Holdings Inc’s revenue for the current quarter will be 54.9M. The company’s revenue for the corresponding quarters a year ago was 44.39M and 40.64M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 35.17%. The estimates for the next quarter sales put growth at 35.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 38.13%. The 2025 estimates are for Xeris Biopharma Holdings Inc earnings to increase by 21.65%.
XERS Dividends
Xeris Biopharma Holdings Inc is expected to release its next quarterly earnings report in February.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.92% of Xeris Biopharma Holdings Inc shares while 43.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 45.75%. There are 43.96% institutions holding the Xeris Biopharma Holdings Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.3531% of the shares, roughly 10.33 million XERS shares worth $23.25 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.4492% or 7.66 million shares worth $17.23 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 4.25 shares estimated at $13.62 million under it, the former controlled 2.85% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.41% of the shares, roughly 3.59 shares worth around $11.5 million.
